May 1, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Therapies, Type 2 Diabetes, Type 2 Diabetes 4,286 views Why do some patients see impressive results with GLP-1 therapies while others barely respond
doi: 10.1038/s41580-020-0230-3 3 ShekhovaE
The most frequently reported AEs are gastrointestinal in nature, including nausea, vomiting, diarrhea and constipation, reflective of the effects of GLP-1 agonists on the gastrointestinal system
Retatrutide acts on GLP-1, GIP and glucagon in a single peptide, where earlier compounds act on only one or two
There has long been a concern in the scientific community regarding the risk of pancreatitis and pancreatic cancer in those using GLP-1RA and the related DPP-4 inhibitors
If you need the practical steps for arranging testing, our How to get a blood test page explains the process